BOSTON SCIENTIFIC CORP

NYSE: BSX (Boston Scientific Corporation)

Last update: 5 days ago, 6:51AM

95.61

-0.50 (-0.52%)

Previous Close 96.11
Open 96.85
Volume 16,196,348
Avg. Volume (3M) 9,787,487
Market Cap 141,736,280,064
Price / Earnings (TTM) 51.13
Price / Earnings (Forward) 27.78
Price / Sales 7.42
Price / Book 6.09
52 Weeks Range
85.98 (-10%) — 109.50 (14%)
Earnings Date 4 Feb 2026
Profit Margin 11.58%
Operating Margin (TTM) 20.09%
Diluted EPS (TTM) 1.37
Quarterly Revenue Growth (YOY) 20.90%
Quarterly Earnings Growth (YOY) 36.20%
Total Debt/Equity (MRQ) 52.16%
Current Ratio (MRQ) 1.45
Operating Cash Flow (TTM) 3.81 B
Levered Free Cash Flow (TTM) 2.32 B
Return on Assets (TTM) 5.28%
Return on Equity (TTM) 9.50%

Market Trend

Short Term Medium Term
Industry Medical Devices (US) Mixed Mixed
Medical Devices (Global) Mixed Mixed
Stock Boston Scientific Corporation Bullish Bullish

AIStockmoo Score

0.5
Analyst Consensus 5.0
Insider Activity NA
Price Volatility 4.5
Technical Moving Averages -3.5
Technical Oscillators -4.0
Average 0.50

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
BSX 142 B - 51.13 6.09
SYK 139 B 0.46% 47.88 6.24
PHG 26 B - 142.68 2.06
ABT 217 B 0.47% 15.65 4.28
MDT 126 B 1.42% 26.64 2.56
EW 49 B - 36.95 4.92

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Sector Healthcare
Industry Medical Devices
Investment Style Large Core
% Held by Insiders 0.18%
% Held by Institutions 93.22%

Ownership

Name Date Shares Held
Bollard Group Llc 30 Sep 2025 19,733,573
52 Weeks Range
85.98 (-10%) — 109.50 (14%)
Price Target Range
110.00 (15%) — 140.00 (46%)
High 140.00 (UBS, 46.43%) Buy
Median 129.00 (34.92%)
Low 110.00 (Evercore ISI Group, 15.05%) Buy
Average 127.58 (33.44%)
Total 12 Buy
Avg. Price @ Call 97.68
Firm Date Target Price Call Price @ Call
Truist Securities 18 Dec 2025 120.00 (25.51%) Buy 96.11
23 Oct 2025 130.00 (35.97%) Buy 102.39
Canaccord Genuity 17 Dec 2025 131.00 (37.01%) Buy 94.48
23 Oct 2025 132.00 (38.06%) Buy 102.39
RBC Capital 17 Dec 2025 130.00 (35.97%) Buy 94.48
29 Sep 2025 125.00 (30.74%) Buy 97.04
BTIG 21 Nov 2025 132.00 (38.06%) Buy 96.88
22 Oct 2025 132.00 (38.06%) Buy 103.85
Morgan Stanley 23 Oct 2025 130.00 (35.97%) Buy 102.39
UBS 23 Oct 2025 140.00 (46.43%) Buy 102.39
Wells Fargo 23 Oct 2025 125.00 (30.74%) Buy 102.39
Needham 17 Oct 2025 121.00 (26.56%) Buy 99.24
01 Oct 2025 121.00 (26.56%) Buy 95.85
Evercore ISI Group 07 Oct 2025 110.00 (15.05%) Buy 95.90
Barclays 02 Oct 2025 136.00 (42.24%) Buy 96.22
Baird 01 Oct 2025 128.00 (33.88%) Buy 95.85
Leerink Partners 01 Oct 2025 128.00 (33.88%) Buy 95.85
Show more

No data within this time range.

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria